Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy on beta-cell Function and Glycemic Remission Rate in Newly Diagnosed Type 2 Diabetic Patients

Trial Profile

Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy on beta-cell Function and Glycemic Remission Rate in Newly Diagnosed Type 2 Diabetic Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Exenatide (Primary) ; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Sep 2016 Primary endpoint of glycemic remission rate has been met, according to results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
    • 05 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top